Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F24%3AA25039NA" target="_blank" >RIV/61988987:17110/24:A25039NA - isvavai.cz</a>

Výsledek na webu

<a href="https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38" target="_blank" >https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2024013212" target="_blank" >10.1182/bloodadvances.2024013212</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Popis výsledku v původním jazyce

This study explores the potential of targeting CD38 in older patients with acute myeloid leukemia (AML) using isatuximab and a novel trispecific CD38/CD3×CD28 T-cell engager (CD38-TCE). CD38 expression was analyzed in AML patients ineligible for intensive chemotherapy, revealing widespread but variable CD38 levels. Preclinical studies demonstrated that isatuximab and CD38-TCE effectively induced tumor cell lysis through immune cell activation, with CD38-TCE showing a stronger effect independent of CD38 density. These findings suggest that CD38-targeting immunotherapies could be promising treatment options for AML, particularly in older patients. Further in vivo studies are warranted.

Název v anglickém jazyce

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Popis výsledku anglicky

This study explores the potential of targeting CD38 in older patients with acute myeloid leukemia (AML) using isatuximab and a novel trispecific CD38/CD3×CD28 T-cell engager (CD38-TCE). CD38 expression was analyzed in AML patients ineligible for intensive chemotherapy, revealing widespread but variable CD38 levels. Preclinical studies demonstrated that isatuximab and CD38-TCE effectively induced tumor cell lysis through immune cell activation, with CD38-TCE showing a stronger effect independent of CD38 density. These findings suggest that CD38-targeting immunotherapies could be promising treatment options for AML, particularly in older patients. Further in vivo studies are warranted.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BLOOD ADVANCES

ISSN

2473-9529

e-ISSN

2473-9537

Svazek periodika

—

Číslo periodika v rámci svazku

15

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

3875-3879

Kód UT WoS článku

001284281200001

EID výsledku v databázi Scopus

2-s2.0-85201467266